Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award. The annual TechConnect Business Innovation Awards program recognizes the top 15% of submitted technologies as ranked by the selection committee in multiple categories from the Energy, Nanomaterials, Health and Medicine, AI, Robotics, and others. The Summit is co-organized by SBIR/STTR Innovation Program and co-located with Defense Innovation Summit.

Garching/Munich, Germany, and Houston, Texas, U.S., December 08, 2020: ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has issued the Drug Master File (DMF no. 34938) for ITM’s next generation Germanium-68/Gallium-68 (⁶⁸Ge/⁶⁸Ga) Generator, distributed under the brand name GeGant®.The DMF will allow parties interested in developing new drugs for the U.S. market to refer to the DMF and use GeGant® in clinical tests for radiopharmaceuticals and in other settings.

ST. LOUIS, Dec. 09, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has granted Detectnet Transitional Pass-Through Status (code C9068) effective January 1, 2021. The descriptor for Detectnet will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. C9068 will be used to bill Detectnet for Medicare patients seen in the hospital outpatient department.

Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.

“It is an honor to join the world-class team at Radiomedix to guide in the areas of strategy and finance at a time when the company is at the brink of creating new treatment modalities in neuroendocrine cancers, said Faridian.”

Houston, TX and St. Louis, MO, Sept. 07, 2020 (GLOBE NEWSWIRE) -RadioMedix Inc. and its commercial partner Curium announced today that Detectnet^TM (copper Cu 64 dotatate injection) was approved by the U.S. Food and Drug Administration (FDA). Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Curium expects to launch Detectnet immediately with doses available through various nuclear pharmacies or directly from Curium.  

ITM’s long-term partner RadioMedix is producing and distributing GeGant^® for the U.S. market

GARCHING, Germany & MUNICH & HOUSTON--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, announced today that ITM has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for ITM’s next generation Germanium-68/Gallium-68 (⁶⁸Ge/⁶⁸Ga) Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant^®.

Houston, TX, USA and Garching, Germany. RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.   The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188

Houston, Jan. 02, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National Institute of Health (NIH) SBIR/STTR

Houston and St Louis, Jan. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the New Drug Application for copper Cu 64 dotatate injection was filed with the U.S.